Maria Rossing

University of Copenhagen — Denmark

Biochemistry, Genetics and Molecular Biology · Life Sciences

31h-index3.2kcitations212works1.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

BRCA gene mutations in cancer(61), Cancer Genomics and Diagnostics(25), PARP inhibition in cancer therapy(22), Platelet Disorders and Treatments(16), Ovarian cancer diagnosis and treatment(15)

Publications171 total

Harmonization of Reporting of ALK Genetic Alterations in Neuroblastoma
Journal of Molecular Diagnostics·2025Open Access
Dietary Supplement Use and Life Expectancy After Breast Cancer–The Danish Diet, Cancer and Health Cohort
Journal of Nutrition·2025
Enhancing HER2-low breast cancer detection with quantitative transcriptomics
npj Breast Cancer·2025· 2 citedOpen Access
Mutational Landscape Assessed in Tumor Tissue and Circulating Tumor DNA During Treatment of Patients with HER2/ERBB2-Mutated Solid Tumors
BMC Cancer·2025Open Access
The class II myosin MYH4 safeguards genome integrity and suppresses tumor progression
Journal of Clinical Investigation·2025Open Access
Timely germline BRCA testing after invasive breast cancer promotes contralateral risk-reducing mastectomy and improves survival: an observational retrospective study
Breast Cancer Research and Treatment·2025· 2 citedOpen Access
HRD status variation in consecutive tumour biopsies in a pan-cancer cohort: a descriptive single-center study including patients from the Phase 1 Unit, Copenhagen University Hospital, Rigshospitalet
Cancer Genetics·2025Open Access
SupplementaryGeneTable S1 from Beyond HRD Status: Unraveling Genetic Variants Impacting PARP Inhibitor Sensitivity in Advanced Ovarian Cancer
2025Open Access
Supplementary Material from Beyond HRD Status: Unraveling Genetic Variants Impacting PARP Inhibitor Sensitivity in Advanced Ovarian Cancer
2025Open Access
G6PC3 promotes genome maintenance and is a candidate mammary tumor suppressor
JCI Insight·2025Open Access
Precision screening facilitates clinical classification of BRCA2-PALB2 binding variants with benign and pathogenic functional effects
Journal of Clinical Investigation·2025· 1 citedOpen Access
SupplementaryGeneTable S1 from Beyond HRD Status: Unraveling Genetic Variants Impacting PARP Inhibitor Sensitivity in Advanced Ovarian Cancer
2025Open Access
Supplementary Material from Beyond HRD Status: Unraveling Genetic Variants Impacting PARP Inhibitor Sensitivity in Advanced Ovarian Cancer
2025Open Access
Comprehensive mapping elucidates high risk genotypes in primary metastatic breast cancer
Neoplasia·2025· 2 citedOpen Access
Germline BRCA testing in Denmark following invasive breast cancer: Progress since 2000
Acta Oncologica·2025· 2 citedOpen Access
Nuclear N-WASP Induces Actin Polymerization in the Nucleus with Cortactin as an Essential Factor
Cells·2025Open Access
Figure 4 from Beyond HRD Status: Unraveling Genetic Variants Impacting PARP Inhibitor Sensitivity in Advanced Ovarian Cancer
2024Open Access
SupplementaryGeneTable S1 from Beyond HRD Status: Unraveling Genetic Variants Impacting PARP Inhibitor Sensitivity in Advanced Ovarian Cancer
2024Open Access
Figure 2 from Beyond HRD Status: Unraveling Genetic Variants Impacting PARP Inhibitor Sensitivity in Advanced Ovarian Cancer
2024Open Access
Table 1 from Beyond HRD Status: Unraveling Genetic Variants Impacting PARP Inhibitor Sensitivity in Advanced Ovarian Cancer
2024Open Access
page 1 of 9Next →

Frequent Co-authors

Finn Cilius Nielsen(28), Christian Godballe(8), Oľga Østrup(7), Ole Winther(6), Jes Sloth Mathiesen(6), Åse Krogh Rasmussen(6), Ulla Feldt‐Rasmussen(6), Thomas van Overeem Hansen(6), Lennart Friis‐Hansen(5), Bodil Norrild(5), Anja Lisbeth Frederiksen(5), Amanda B. Spurdle(5), Sophie Krieger(5), Mette Gaustadnes(5), Bent Ejlertsen(5), Anne‐Marie Gerdes(5), Martin Glud(4), Raphaël Leman(4), Pascaline Gaildrat(4), Gérald Le Gac(4)